Biohaven (BHVN) Completes Enrollment in RISE3 Trial

Biohaven Ltd. (NYSE:BHVN) is one of the 10 Best Performing American Stocks in June 2026.

On June 30, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled study evaluating opakalim for refractory focal epilepsy. Opakalim is Biohaven’s selective Kv7.2/7.3 channel activator, and top-line results from the study are expected in 2H 2026.

On June 29, Biohaven announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves’ disease. BHV-1300 is the first MoDE extracellular protein degrader, described by the company as a novel small molecule IgG1, 2, and 4 degrader that uses the body’s clearance machinery to eliminate the IgG1 TSHR autoantibody driving Graves’ disease.

On June 26, Deutsche Bank raised the firm’s price target on Biohaven to $20 from $15 and kept a Buy rating on the shares. Deutsche Bank said the company’s troriluzole in spinocerebellar ataxia could be the next beneficiary of recent FDA reversals.

Biohaven (BHVN) Completes Enrollment in RISE3 Trial

Miriam Doerr Martin Frommherz/Shutterstock.com

Biohaven Ltd. (NYSE:BHVN) focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

While we acknowledge the risk and potential of BHVN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BHVN and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1